As you will see, the reviewers are supportive of publication of your manuscript here, and provide constructive comments that will allow you to further strengthen you work. We would thus like to invite you to submit a revised version of your manuscript, addressing the comments made by rev#2 and #3.
t +49 6221 8891 502 e a.leibfried@life-science-alliance.org www.life-science-alliance.org ---------------------------------------------------------------------------A. THESE ITEMS ARE REQUIRED FOR REVISIONS --A letter addressing the reviewers' comments point by point.
--An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
--High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, http://www.life-science-alliance.org/authors --Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title and running title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.
B. MANUSCRIPT ORGANIZATION AND FORMATTING:
Full guidelines are available on our Instructions for Authors page, http://www.lifescience-alliance.org/authors
We encourage our authors to provide original source data, particularly uncropped/processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excelfile per figure for this information. These files will be linked online as supplementary "Source Data" files. ***IMPORTANT: It is Life Science Alliance policy that if requested, original data images must be made available. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original microscopy and blot data images before submitting your revision.*** ---------------------------------------------------------------------------Reviewer #1 (Comments to the Authors (Required)):
Zelazowska et al. assess the impact of gHV infection on GC B cell repertoires using an elegant MHV68 infection model, which allows tracking of infected cells by viral EYFP expressing. By flow cytometry the authors assess the GC response at cellular level over the infection and compare the Ig repertoire of infected and non-infected GC B cells at single-cell level in individual mice. Their comprehensive analysis of a large number of several hundred paired Ig gene sequences provides clear evidence that MHV-infected and non-infected GC B cells in the same animals express different Ig genes. Light chain isotype and VH usage, SHM load, and clone analyses provide independent evidence. Lambda light chains, Ighv 10-1 and Ighj 4 genes are overrepresented in infected cells, which also frequently belong to expanded and diversified cell clusters with high numbers of SHM compared to their non-infected counterparts. Confirmation for the strong clonal expansion and lack of clonal overlap between infected and non-infected cells comes from bulk analyses. It seems that the differences between the infected and non-infected cells may be even larger if the authors had performed clonal suppression analyses and normalizations to count for the differences in sampling depth. Entropy analyses might be helpful, however, none of these analyses are required given the strong differences that the authors observe. As is, the data is highly valuable and of great relevance for our understanding of the role of HV infections in biasing B cell repertoires. The data is of high quality, the experimental approaches are well described, and the manuscript is well written. The authors present a careful and well-justified interpretation of their findings in the context of the available literature. Therefore, the manuscript merits publication without any changes.
Reviewer #2 (Comments to the Authors (Required)):
Manuscript Nr: LSA-2019-00526 Zelazowska et al., "Gammaherpesvirus Infected Germinal Center Cells Express A Distinct Immunoglobulin Repertoire"
The authors demonstrate that murine gamma herpesvirus 68 (MHV68) infection in mice skews their B cell repertoire. As previously reported for the human gamma herpesvirus Kaposi sarcoma associated herpesvirus (KSHV) MHV68 infected cells are enriched for lambda light chain usage. Furthermore, also their variable region usage in the BCR heavy chain is skewed, while isotype and somatic hypermutation characteristics do not differ from uninfected germinal center B cells in the same animals. From these data the authors speculate that MHV68 could shape the specificity of their infected B cells, possibly eliciting autoreactivities that could support the survival of their host cells.
These are interesting findings, but no information is provided on the infected B cell specificities. Some information on the possibly autoimmune or virus specific nature of the infected B cell specificities would significantly strengthen the novelty of the submitted study.
Major comments: 1. The authors report BCR modulation in MHV68 infected B cells. It would be interesting if MHV68 could directly induce the respective machinery, as has been previously reported for the Epstein Barr virus (EBV). Along these lines the authors should investigate if AID and RAG expression is induced upon in vitro mouse B cell infection by MHV68? 2. From the reported data it remains unclear what the function of BCR heavy chain variable region and lambda light chain enrichment in MHV68 infected B cells could be. Would sorted infected B cells depending on ther BCR specificity survive better or worse upon adoptive transfer into non-infected mice? 3. Are any of the enriched BCRs of MHV68 infected B cells virus specific or autoreactive? The authors speculate that MHV68 aims for an alteration in the BCR specificity of its infected B cells. The novelty of the submitted manuscript could be significantly increased if some of the BCR specificities by recombinantly expressing them as antibodies could be checked for autoreactivity and virus specificity.
Minor comments: 1. Since the authors found a lambda lc shift with MHV68 in this study that is reminiscent of KSHV, I would suggest that they rather emphasize the similarities with KSHV in the abstract. This would also be more consistent with the subfamily of gamma-herpesviruses to which both MHV68 and KSHV belong.
In summary, the authors describe interesting alterations in the BCR repertoire of MHV68 infected B cells. In order to interpret these findings, however, some more information on the function of the resulting immunoglobulins should be provided.
Reviewer #3 (Comments to the Authors (Required)):
Human gamma-herpesviruses like EBV and KSHV establish latent infection in memory B cells. It is well established that they reach this compartment by driving infected cells through GC reactions. Less is known how the virus exploits GC reactions. This study addresses this issue, in particular, an outstanding question, that is, the BCR specificity of the infected cells. The study is very well performed and data of high quality with overlapping methodologies that produce same observations and conclusions. Specifically, it is shown that: 1) there is a similar distribution of isotype expression in MHV68 infected CG B cells indicating GC driven response; 2) infected GC B cells display a shift towards Igl usage with Igk paired similar frequency; 3) significantly small clonal overlap between infected versus non-infected GC B cells; 4) somatic hypermutation in infected GC B cells. Together, these data show that MHV68 infected GC B cells are a specific B subset and is coherent with previous studies demonstrating that infection of GC B cells is not a stochastic event and not driven by ongoing humoral responses to viral antigens. The authors raise the hypothesis of MZ B cells being a possible seeding candidate. I think that is the most likely explanation. In this context the first study showing MZ B cells infection should be cited (J Virol. 2003 Jul; 77(13) :7308-18). It would have been significant if this study had addressed the antigen specificity of infected B cells, namely, the possibility discussed of auto-antigen reactivity. Hence, BCR specificity of infected B cells remains elusive. Interesting to note that given that EBV infects virtually all human population, evolution pressure to infect a restricted BCR repertoire that do not induce pathology is very likely.
1st Authors' Responses to Reviewers January 3, 2020
We thank the editor and reviewers for their effort and detailed critique on our manuscript. In response to reviewer #2 & #3 comments we include new data (figure 7 and S4). Changes in the updated manuscript are highlighted. Reviewer comments and our detailed response (in Bold) are included below.
All the reviewers made supportive comments.
Reviewer #1: "The authors present a careful and well-justified interpretation of their findings in the context of the available literature. Therefore, the manuscript merits publication without any changes."
Reviewer #2 was also supportive stating "These are interesting findings" with the suggestion, "Some information on the possibly autoimmune or virus specific nature of the infected B cell specificities would significantly strengthen the novelty of the submitted study."
Reviewer #3: "This study addresses this issue, in particular, an outstanding question, that is, the BCR specificity of the infected cells. The study is very well performed and data of high quality with overlapping methodologies that produce same observations and conclusions." Included was the comment that "antigen specificity of infected B cells, namely, the possibility discussed of auto-antigen reactivity" would increase the significance.
As detailed below we address a question of antigen specificity of the BCR from infected cells. This is included as new data in additional Figure 7 and S4. We have now recombinantly produced antibodies and analyzed reactivity to selfnuclear and viral antigens from both MHV+ and MHV-populations. While find no increase in ANA reactivity, we find a significant drop in anti-viral reactivity of antibodies from the MHV+ population. We feel this additional data addresses the key comments by reviewers and increases the significance of this study.
These are interesting findings, but no information is provided on the infected B cell specificities. Some information on the possibly autoimmune or virus specific nature of the infected B cell specificities would significantly strengthen the novelty of the submitted study. Figures 7 and S4) . We agree that this is an interesting point. We attempted to address this issue, as suggested by the reviewer, by infecting primary B cells in vitro. Although the primary cells infected with a good efficiency, infected cells rapidly began dying. We posit that the MHV68 infection of B cells in vitro induced an almost complete lytic program. We feel that measuring AID and RAG1/2 expression in such dying cells would not be physiologically relevant. We are also analyzing gene expression from infected germinal center cells in vivo. Preliminary results do not indicate an upregulation in AID and RAG1/2 however additional analysis is needed that will take significant time and effort.
We address this point in major comment #3 below and include new data (New
2. From the reported data it remains unclear what the function of BCR heavy chain variable region and lambda light chain enrichment in MHV68 infected B cells could be. Would sorted infected B cells depending on ther BCR specificity survive better or worse upon adoptive transfer into non-infected mice?
We agree this is a very interesting point. However this study did not conduct an analysis of survival and we feel this is beyond the scope of this current study.
3. Are any of the enriched BCRs of MHV68 infected B cells virus specific or autoreactive? The authors speculate that MHV68 aims for an alteration in the BCR specificity of its infected B cells. The novelty of the submitted manuscript could be significantly increased if some of the BCR specificities by recombinantly expressing them as antibodies could be checked for autoreactivity and virus specificity.
Thank you for commenting, this was an excellent suggestion that reviewer 3 also mentioned. We address this point with new data included in New Figure 7 and S4. To determine if BCRs from the analyzed cells were reactive to self or viral antigens we cloned and produced a representative number of antibodies from the infected and non-infected populations. Using an ANA ELISA assay, we found no significant gain of self-reactivity. We assessed anti-viral reactivity by staining 3T12 cells that were either mock treated or infected and analyzing by flow cytometry. We found that the percentage of antibodies that were reactive against virus-infected cells was significantly lower in the MHV+ population than the MHV-.
Thank you for pointing out the Rhadinovirus parallels and overlap of Lambda LC shift with KSHV. Since we focused on germinal center cells we drew parallels to EBV. We now also mention KSHV in the abstract.
In summary, the authors describe interesting alterations in the BCR repertoire of MHV68 infected B cells. In order to interpret these findings, however, some more information on the function of the resulting immunoglobulins should be provided. Figure 7 and S4.
As mentioned above, we address this point with new data included in New
Human gamma-herpesviruses like EBV and KSHV establish latent infection in memory B cells. It is well established that they reach this compartment by driving infected cells through GC reactions. Less is known how the virus exploits GC reactions. This study addresses this issue, in particular, an outstanding question, that is, the BCR specificity of the infected cells. The study is very well performed and data of high quality with overlapping methodologies that produce same observations and conclusions. Specifically, it is shown that: 1) there is a similar distribution of isotype expression in MHV68 infected CG B cells indicating GC driven response; 2) infected GC B cells display a shift towards Igl usage with Igk paired similar frequency; 3) significantly small clonal overlap between infected versus non-infected GC B cells; 4) somatic hypermutation in infected GC B cells. Together, these data show that MHV68 infected GC B cells are a specific B subset and is coherent with previous studies demonstrating that infection of GC B cells is not a stochastic event and not driven by ongoing humoral responses to viral antigens. The authors raise the hypothesis of MZ B cells being a possible seeding candidate. I think that is the most likely explanation. In this context the first study showing MZ B cells infection should be cited (J Virol. 2003 Jul; 77(13) :7308-18).
Thank you for pointing out the reference omission. We now include this reference
It would have been significant if this study had addressed the antigen specificity of infected B cells, namely, the possibility discussed of auto-antigen reactivity. Hence, BCR specificity of infected B cells remains elusive. Interesting to note that given that EBV infects virtually all human population, evolution pressure to infect a restricted BCR repertoire that do not induce pathology is very likely.
As also mentioned above in response to reviewer two. We address this point with new data included in New Figure 7 and S4. To determine if BCRs from the analyzed cells were reactive to self or viral antigens we cloned and produced a representative number of antibodies from the infected and noninfected populations. Using an ANA ELISA assay, we found no significant gain of self-reactivity. We assessed anti-viral reactivity by staining 3T12 cells that were either mock treated or infected and analyzing by flow cytometry. We found that the percentage of antibodies that were reactive against virusinfected cells was actually significantly lower in the MHV+ population than the MHV-.
2nd Editorial Decision 27 January 2020 If you are planning a press release on your work, please inform us immediately to allow informing our production team and scheduling a release date.
To upload the final version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.
To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.
A. FINAL FILES:
These items are required for acceptance.
--High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, http://www.life-science-alliance.org/authors --Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.
B. MANUSCRIPT ORGANIZATION AND FORMATTING:
We encourage our authors to provide original source data, particularly uncropped/processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excelfile per figure for this information. These files will be linked online as supplementary "Source Data" files.
**Submission of a paper that does not conform to Life Science Alliance guidelines will delay the acceptance of your manuscript.** **It is Life Science Alliance policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.** **The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements.** **Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.** Thank you for your attention to these final processing requirements. Please revise and format the manuscript and upload materials within 7 days.
Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.
Sincerely, Andrea Leibfried, PhD Executive Editor Life Science Alliance Meyerhofstr. 1 69117 Heidelberg, Germany t +49 6221 8891 502 e a.leibfried@life-science-alliance.org www.life-science-alliance.org The authors demonstrate that murine gamma herpesvirus 68 (MHV68) infection in mice skews their B cell repertoire. As previously reported for the human gamma herpesvirus Kaposi sarcoma associated herpesvirus (KSHV) MHV68 infected cells are enriched for lambda light chain usage. Furthermore, also their variable region usage in the BCR heavy chain is skewed, while isotype and somatic hypermutation characteristics do not differ from uninfected germinal center B cells in the same animals. From these data the authors speculate that MHV68 could shape the specificity of their infected B cells, possibly eliciting autoreactivities that could support the survival of their host cells.
In their revised manuscript version, the authors have addressed my previous concerns. They demonstrate that MHV68 does not seem to up-regulate the immunoglobulin recombination and hypermutation machinery and does not seem to favor auto-or virus-reactive B cell populations during its infection. Therefore, the survival experiment (previous major comment #2) would have been very informative.
As reviewer #3 points out, it would be beneficial for MHV68 to establish persistence in B cells that provide tonic signaling via their BCR for survival, but do not get activated through viral or self-antigens. Despite this omission, the additional experiments and discussion have significantly improved the manuscript.
The finding that γHV68 subverts GC selection to expand in a specific B cell subset to gain access to long-lived memory B cells is not new to the field: this study`s main conclusion. Novel would be the antigenic specificity of the BCR of infected cells, which was not revealed by this study despite the several experimental approaches. I acknowledge the effort made by the authors to address BCR specificity using recombinant antibody methodology and ANA (anti-nuclear antibodies) characteristic for systemic, autoimmune-mediated diseases. This assay failed to give a positive hit. Hence, this study conclusions, after review, are still unchanged but to reinforce that there is no associated autoimmune cells in γHV68 B cell infection. Nevertheless, the authors continue to favor the message that: "With the establishment of this cloning pipeline, future analysis can address earlier time points and whether there is a connection to self-reactive BCRs during the initial cell infection." I find this unnecessary speculative bias.
2nd Authors' Response to Reviewers January 28, 2020 RE: Life Science Alliance Manuscript -Editorial Decision LSA-2019-00526R
Dear Dr. Leibfried
Thank you for your positive decision to publish our manuscript pending final minor revisions.
You requested the following revisions: -Please address reviewer #3's remaining concerns via text changes -Please upload the supplementary tables and include a short legend for them in the main manuscript file
We have made the following changes:
We have removed the text reviewer #3 described as speculative and uploaded the supplementary tables with a short legend in the main manuscript, included in the section with supplemental figure legends.
The FINAL FILES include the above revisions and is submitted as --An editable version of the final text.
--High-resolution figure, supplementary figures The final published version of your manuscript will be deposited by us to PubMed Central upon online publication.
Your manuscript will now progress through copyediting and proofing. It is journal policy that authors provide original data upon request.
Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.
***IMPORTANT: If you will be unreachable at any time, please provide us with the email address of an alternate author. Failure to respond to routine queries may lead to unavoidable delays in publication.*** Scheduling details will be available from our production department. You will receive proofs shortly before the publication date. Only essential corrections can be made at the proof stage so if there are any minor final changes you wish to make to the manuscript, please let the journal office know now.
DISTRIBUTION OF MATERIALS:
Authors are required to distribute freely any materials used in experiments published in Life Science Alliance. Authors are encouraged to deposit materials used in their studies to the appropriate repositories for distribution to researchers.
You can contact the journal office with any questions, contact@life-sciencealliance.org
Again, congratulations on a very nice paper. I hope you found the review process to be constructive and are pleased with how the manuscript was handled editorially. We look forward to future exciting submissions from your lab.
Sincerely, Andrea Leibfried, PhD Executive Editor Life Science Alliance
